DEC 2014 ARTICLE LIST >>
PharmaTutor (December- 2014)
ISSN: 2347 - 7881
(Volume 2, Issue 12)
Received On: 03/05/2014; Accepted On: 26/10/2014; Published On: 01/12/2014
AUTHORS: Duvvuru Ashok Kumar1*, Languluri Reddenna2
1Department of Pharm-D, P. Rami Reddy Memorial College of Pharmacy, Kadapa, Andhra Pradesh, India
2Department of Pharmacy Practice, Rajiv Gandhi Institute of Medical Sciences, Kadapa, Andhra Pradesh, India
ashok.alex11@gmail.com
ABSTRACT: MS is the most common inflammatory-demyelinating disease of the central nervous system (CNS). MS is estimated to affect 400,000 persons in the United States and 2 million people worldwide. Women are affected twice as frequently as men, between the ages of 20 and 40. The etiology of MS is still unknown, but according to current data the disease develops in genetically susceptible individuals and may require additional environmental triggers. In this paper, we present the insight on simple cure for multiple sclerosis.
How to cite this article: AK Duvvuru, L Reddenna; Multiple Sclerosis: Overview on Simple Cure; PharmaTutor; 2014; 2(12); 29-32
[ABSTRACT WITH CITATION] [VIEW AS HTML]
REFERENCES:
1. Rodriguez M, Siva A, Ward J, et al. Impairment, disability, and handicap inmultiple sclerosis: a population-based study in Olmsted County, Minnesota.Neurology 1994; 44:28–33
2. Hauser S. Multiple sclerosis and other demyelinating diseases. In: IsselbacherKJ, Martin JB, Fauci AS, et al, eds. Harrison’s principles of internal medicine. NewYork: McGraw-Hill; 1994:2287–955.
3. Reingold SC. Fatigue and multiple sclerosis. MS News Br Mult Scler Soc 1990; 142:30–316
4. Bagert B, Camplair P, Bourdette D. Cognitive dysfunction in multiplesclerosis: natural history, pathophysiology and management. CNS Drugs2002; 16:445–55
5. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiplesclerosis: a geographically based study. I. Clinical course and disability. Brain1989; 112:133–46
6. Montalban X. Primary progressive multiple sclerosis. Curr Opin Neurol 2005; 18:261–6623. Pashenkov M, Teleshova N, Link H. Inflammation in the central nervoussystem: the role for dendritic cells. Brain Pathol 2003; 13:23–33
7. Hafler DA, Slavik JM, Anderson DE, et al. Multiple sclerosis. Immunol Rev2005;204:208–231
8. Link H. The cytokine storm in multiple sclerosis. Mult Scler 1998;4:12–15
9. Lassmann H. Pathology of multiple sclerosis. In: Compston A, Ebers G, LassmannH, et al, eds. McAlpine’s multiple sclerosis. London: Churchill Livingstone;1998:323–57
10. Steinman L. Multiple sclerosis: a two-stage disease. Nat Immunol 2001;2:762–64
11. Oksenberg JR, Hauser SL. Genetics of multiple sclerosis. Neurol Clin 2005;23:61–75
12. Trapp BD, Ransohoff R, Rudick R. Axonal pathology in multiple sclerosis:relationship to neurologic disability. Curr Opin Neurol 1999;12:295–302
13. Lassmann H. Pathology of multiple sclerosis. In: Compston A, Ebers G, LassmannH, et al, eds. McAlpine’s multiple sclerosis. London: Churchill Livingstone;1998:323–57
14. Italian doctor may have found surprisingly simple cure for Multiple Sclerosis. gizmag.com/ccsvi-multiple-sclerosis-ms-cure-zamboni/13447/
.png)
